Abstract:BackgroundThe objective of this study was to evaluate the outcomes of patients with high‐grade glioma who received treatment with particle radiotherapy.MethodsBetween June 2015 and October 2018, 50 consecutive and nonselected patients with glioblastoma multiforme (n = 34) or anaplastic glioma (n = 16) were treated at the Shanghai Proton and Heavy Ion Center. Twenty‐four patients received proton radiotherapy (at a dose of 60 gray‐equivalents in 30 daily fractions), and 26 patients received proton radiotherapy plus a carbon‐ion radiotherapy (CIRT) boost in various dose‐escalating schemes. All patients received temozolomide because of their age or their O‐6‐methylguanine‐DNA methyltransferase (MGMT) promoter methylation status. Progression‐free survival (PFS) and overall survival (OS) rates, as well as treatment‐induced toxicities, were analyzed.ResultsAt a median follow‐up of 14.3 months (range, 4.8‐39.6 months), the 12‐month and 18‐month OS rates were 87.8% (95% CI, 77.6%‐98.0%) and 72.8% (95% CI, 56.7%‐88.9%), respectively, and the 12‐month and 18‐month PFS rates were 74.2% (95% CI, 60.9%‐87.5%) and 59.8% (95% CI, 43.1%‐76.5%), respectively. Univariate analyses revealed that age (>50 vs ≤50 years), World Health Organization grade (3 vs 4), and Karnofsky performance status (>80 vs ≤80) were significant prognosticators for OS, and IDH mutation and World Health Organization grade were significant for predicting PFS. Furthermore, MGMT promoter methylation, performance status, and age showed a trend toward predicting PFS. No significant predictive factors for PFS or OS were identified in multivariate analyses. Twenty‐nine patients experienced grade 1 treatment‐related acute adverse effects, and 11 developed grade 1 (n = 6) or grade 2 (n = 5) late adverse effect of radiation‐induced brain necrosis. No grade 3, 4, or 5 toxicities were observed.ConclusionsParticle radiotherapy produced 18‐month OS and PFS rates of 72.8% and 59.8%, respectively, with acceptable adverse effects in patients with high‐grade glioma. Particle radiotherapy at a dose ≥60 gray‐equivalents appears to be safe and potentially effective.

Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review

Current status and recent advances in reirradiation of glioblastoma

The Extent of Resection and Adjuvant Treatment Are Beneficial to the Outcome of Secondary Glioblastoma

The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report

Radt-37. Proton Therapy Reirradiation For Recurrent Malignant Glioma: Prospective Analysis From The Proton Collaborative Group

Boron Neutron Capture Therapy for Recurrent Glioblastoma Multiforme: Imaging Evaluation of a Case With Long-Term Local Control and Survival

Long-term outcomes following proton therapy for non-metastatic central nervous system germinoma in children and adolescents

Proton therapy for adult-type diffuse glioma: A systematic review

Particle Radiation Therapy in the Management of Malignant Glioma: Early Experience at the Shanghai Proton and Heavy Ion Center

TMIC-47. SINGLE-CELL TRANSCRIPTOMICS REVEALS ANTITUMOR IMMUNE RESPONSES OF PROTON TREATMENT IN GLIOBLASTOMA

Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes

Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress

Complete radiographic response after proton radiation therapy in the re-irradiation of a diffuse high-grade glioma: A case report

A case report of successful combined intra-arterial immunotherapy and cytokine genetic therapy treatment in a patient with recurrent glioblastoma

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience

Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas

Progress and prospect in tumor treating fields treatment of glioblastoma

P17.05.A TUMOR-TREATING FIELDS COMBINED WITH SECOND-LINE CHEMOTHERAPY REACHED PROGRESSION FREE SURVIVAL OF 8.33 MONTHS IN CHINESE RECURRENT GLIOBLASTOMA

Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis

Radioimmunotherapy of Glioblastoma Multiforme - Current Status and Future Prospects.